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Hepatic resection is currently accepted as the mainstay of curative therapy for localised hepatocellular 
carcinoma or metastatic disease. Evaluation of the patients’ general fitness for this type of major surgery is 
critical since post operative complications is an important cause of postoperative mortality. The Surgical 
Outcome Risk Tool (SORT) [1] is a simple to use risk assessment scoring system that is available for the UK 
population to assess risk of 30 day mortality. Unlike the Physiological and Operative Severity Score (POSSUM) 
[2] the SORT does not require extensive laboratory data for its calculation.  However, the SORT has not been 
validated in populations outside the UK.  Due to the high prevalence of hepatitis B infection, the age-
standardised incidence rate of hepatocellular carcinoma in Hong Kong is over ten times that of the UK [3]. It 
is against this background that we set out to validate the SORT in a population of patients undergoing 
hemihepatectomy in a tertiary hospital in Hong Kong.  
 
After obtaining IRB approval, anonymized data from patients who underwent hemihepatectomy from 2010-
2016 were retrieved from a database administered by the Department of Surgery, Queen Mary Hospital. No 
imputation methods were used, and patient data with any of the six required SORT variables missing were 
excluded from the study. Four hundred and seventy five patients, with a 30-day mortality rate of 0.016% (a 
total of eight patients), were included in the analysis (Table 1). The SORT considers the following variables: 
severity, ASA-PS classification, urgency, risk of surgery, presence of cancer, and age. Hemihepatectomy is 
categorized under high-risk surgery and all the patients were classified under the same severity and urgency 
variables, (i.e. Xmajor/Complex and Expedited, respectively). All cases were cancer patients, predominantly 
hepatocellular carcinoma. Table 1 shows the patient characteristics according to the six SORT variables.   
 
Together with the actual 30-day mortality data, the discriminatory accuracy of SORT was obtained by 
calculating the area under the receiver operating characteristic curve (AUROC) using Statistical Package for 
Social Sciences (SPSS V.22). 
  
The mean SORT risk percentage for hemihepatectomy was 3.94% (±4.24), ranging from 1.25% to 23.06% 
(Figure 1 and Table 2).  With an AUROC of 0.822 (p=0.000), the SORT score should predict risk of death in our 
population well (Figure 1) but, the predicted number of deaths at 30 days is 17, whereas the actual number 
of deaths in our population was 8, indicating that the SORT over-estimated number of deaths by about 43%.  
The co-existence of a high AUROC curve and an over-estimation of 30-day mortality of over 40% seem to be 
at odds. So what exactly does the AUROC curve tell us, and can we rely on this to give us information about 
how good a risk assessment tool is?  
 
AUROC is the usual metric used in validation of scores for risk assessment and it measures discrimination [4].  
Discrimination, in practical terms, means if you were to randomly pick out two patients from the group, the 
one who died at 30 days (the “case”) should have the higher SORT score.  Perfect discrimination (AUROC = 1) 
is achieved if the score is higher in the case compared with the non-case 100 % of the time.   Of course, the 
score has no discriminative powers if it is correct only in 50% of the time (AUROC =0.5), ie, no better than a 
coin toss. An AUROC curve of 0.82 as seen in the current study means that that if you pick any two patients 
out from the group, there is an 82% chance the case had a higher risk score than the non-case (the survivor). 
 
The AUROC also gives you some information about how well the model can rank order cases and non-cases, 
but ranking order overall is not always useful.  Using SORT as an example, a model can have perfect 
discrimination even if every case had a SORT score of say 2% and every non-case of 1%.  Along the same lines, 
a model may also have perfect discriminant capability even if it assigned every case with a SORT score of 
anything from 3 to 30%, and every non-case with a score of 1% or less. In this way, the model has assigned 
someone with a score of 5% the same clinical importance as someone with a score of say 23%.  Clearly using 
these numbers may not be meaningful when trying to explain risk of mortality to the patient.   As the AUROC 
is an aggregate, for anything less than perfect discrimination one cannot tell whether the model performs 
better with high or low SORT scores.  Therefore looking at the AUROC curve alone does not tell us whether 
the discrimination capacity is large enough to permit useful distinctions between those patients at high risk, 
and those at low risk of death post-surgery.  
 
It is suggested here, that when comparing, or validating models of risk assessment, tests of model fit, such as 
likelihood ratio test and Hosmer-Lemeshow test should also be considered [5]. Whilst these tests have been 
criticized, they nevertheless provide a useful measure to identify accuracy in risk assessment models 
according to deciles of risk. In the setting of prospective risk prediction, the proportion of patients classified 
correctly (similar to table 2), rather than the AUROC curve, would seem to have more clinical relevance, and 
this data should be presented in any publication validating risk assessment tools.  
 
  
Figure legends 
 
Figure 1. Bar chart showing distribution of risk scores among 475 patients undergoing hemihepatectomy 
Figure 2. Area under Receiver Operating Characteristics (AUROC) for Surgical Outcome Risk Tool (SORT) 
predicting the 30-day mortality of hemihepatectomy patients. AUROC is 0.822 (95% CI, 0.728 to 0.916). 
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Table 1. Descriptive Patient Characteristics according to the six SORT variables 
 
 No. of patients 
All patients 475 
Mortality 8 
Age 
<65 
≥65 and <80 
≥80 
 
308 
156 
11 
ASA-PS grade 
I 
II 
III 
IV 
V 
 
22 
300 
144 
9 
0 
Urgency of surgery 
Elective 
Expedited 
Urgent 
Immediate 
 
0 
475 
0 
0 
Severity 
Minor 
Intermediate 
Major 
Xmajor/complex 
 
0 
0 
0 
475 
Cancer 475 
Cholangio CA 
Liver metastases  
HCC 
Mixed CA 
Necrotic Tumour 
RPC + Cholangio CA  
41 
85 
337 
7 
2 
3 
ASA-PA, American Society of Anesthesiologists Physical Status; Xmajor, extra major; Cholangio CA, Cholangiocarcinoma; HCC, 
Hepatocellular carcinoma; Mixed Ca, Mixed Hepatocholangiocarcinoma; RPC, Recurrent Pyogenic Cholangitis. 
 
 
  
Table 2. Predicted and observed frequencies of mortality at 30 days post-surgery 
 
SORT Score No. of patients 
(%) 
No. of predicted deaths at 30 
days post-surgery 
No. of observed deaths at 30 
days post-surgery 
1.25 235 (49.47) 3 0 
2.68 82 (17.26) 2 1 
4.93 70 (14.74) 3 2 
5.85 5 (1.05) 0 1 
10.14 68 (14.32) 7 2 
12.11 3 (0.63) 0 1 
20.29 6 (1.26) 1 1 
23.06 6 (1.26) 1 0 
    
Total 17 8 
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